Description

Formamide, n-[3-[[4-[(3-Chloro-4-Fluorophenyl)Amino]-7-Methoxy-6-Quinazolinyl]Oxy]Propyl]-n-(2-Hydroxyethyl)- is a high-purity, advanced pharmaceutical intermediate of significant commercial and research importance. This compound serves as a critical building block in the synthesis of targeted therapeutic agents, particularly within the oncology research and development sector. It is essential for pharmaceutical manufacturers, contract research organizations (CROs), and academic institutions engaged in the development of novel kinase inhibitors and other small-molecule drugs.

Application

• Pharmaceutical Intermediate: Key synthetic precursor in the production of targeted cancer therapeutics, specifically tyrosine kinase inhibitors.
• Oncology Drug Research: Used in the research and development of novel compounds targeting specific genetic pathways in cancer cells.
• Chemical Synthesis: Serves as a specialized building block for constructing complex quinazoline-based molecular architectures in medicinal chemistry.
• Process Development & Scale-up: Employed in optimizing synthetic routes from laboratory-scale to commercial manufacturing for active pharmaceutical ingredients (APIs).
• Reference Standard: Utilized as a high-purity analytical standard for quality control and regulatory submissions in drug development pipelines.

Basic Information

Product Name	Formamide, n-[3-[[4-[(3-Chloro-4-Fluorophenyl)Amino]-7-Methoxy-6-Quinazolinyl]Oxy]Propyl]-n-(2-Hydroxyethyl)-
CAS No.	847949-54-6
Molecular Formula	C23H24ClFN4O4
Molecular Weight	474.91 g/mol
Synonyms	N-[3-[[4-[(3-Chloro-4-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]propyl]-N-(2-hydroxyethyl)formamide; Afatinib Impurity 41; Afatinib Intermediate; BIBW 2992 Intermediate; (3-Chloro-4-fluorophenyl)-[7-methoxy-6-[3-[(2-hydroxyethyl)(formyl)amino]propoxy]quinazolin-4-yl]amine; Giotrif Intermediate; Gilotrif Intermediate; Tovok Intermediate
EINECS	Contact for details

Quality Control

Our Formamide, n-[3-[[4-[(3-Chloro-4-Fluorophenyl)Amino]-7-Methoxy-6-Quinazolinyl]Oxy]Propyl]-n-(2-Hydroxyethyl)- is manufactured under strict quality systems to ensure batch-to-batch consistency and high purity suitable for pharmaceutical R&D. Production adheres to cGMP (current Good Manufacturing Practice) guidelines where applicable. Each batch is supported by a comprehensive Certificate of Analysis (COA) detailing identity, purity, and impurity profiles, available upon request.

Storage

Preserve in a tightly closed container, protected from light. Store in a cool, dry place at a controlled room temperature (typically 15-25°C). The compound may be hygroscopic (moisture-sensitive); ensure containers are sealed under an inert atmosphere if specified. Keep away from strong oxidizing agents.

Specification

Item	Specification
Appearance	White to off-white solid
Identification (HPLC)	Conforms to reference standard
Identification (IR)	Conforms to structure
Assay (HPLC)	≥ 98.0%
Related Substances (HPLC)	Total impurities ≤ 2.0% Any single unknown impurity ≤ 0.5%
Residual Solvents (GC)	Complies with ICH Q3C guidelines
Loss on Drying	≤ 0.5% w/w

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.